# ModeX Therapeutics

Source: https://onco.cc/companies/modex-therapeutics/  
OnCo record `modex-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ModeX Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the tetraspecific T-cell engagers MDX2001 and MDX2003 in biliary tract cancer, cervical cancer, colorectal cancer and endometrial cancer.

## Summary

ModeX Therapeutics develops multispecific antibodies and nanoparticle vaccines for cancer and infectious disease. Its oncology pipeline includes MDX2001 (cMET x Trop2 x CD3 x CD28) for solid tumours and MDX2003 (CD19 x CD20 x CD3 x CD28) for B-cell leukaemia and lymphoma, both tetraspecific T-cell engagers. It is a wholly owned subsidiary of OPKO Health. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06239194 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors) and NCT07249905 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: ModeX Therapeutics, An OPKO Health Company
- Tags: ctgov-sponsor
- HQ: Weston, Massachusetts
- Type: biotech
- Website: https://www.modextherapeutics.com

## Sources

- Official website: https://www.modextherapeutics.com
- ClinicalTrials.gov: trials led by ModeX Therapeutics: https://clinicaltrials.gov/search?lead=ModeX%20Therapeutics%2C%20An%20OPKO%20Health%20Company

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- trials: [Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06239194/), [Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma](https://onco.cc/trials/nct07249905/)

---
JSON: https://onco.cc/api/v1/entities/modex-therapeutics.json